Published in
Elsevier, The Lancet, 10105(390), p. 1853-1862, 2017
DOI: 10.1016/s0140-6736(17)31601-x
Links
Tools
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Journal article published in 2017 by
Honghong Zhou,
Jacob Schachter,
Antoni Ribas,
Paul C. Lorigan,
Bart Neyns,
Laurent Mortier,
Teresa M. Petrella,
Georgina V. Long,
Caroline Robert,
Jean-Jacques Grob,
Ana Arance,
Catriona McNeil,
Michal Lotem,
Matteo S. Carlino 
,
Adil Daud
and other authors.
,
Adil Daud
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysis.